New GLP-1-based obesity drugs like Ozempic and Wegovy are reshaping health care and society. The Obesity Revolution is an in-depth exploration of how these GLP-1 drugs are reshaping science, business, health care, and society. Discover how these groundbreaking treatments are making waves in medical circles and beyond.

Dive into the rapidly evolving landscape of obesity medications, where pharma giants like Novo Nordisk and Eli Lilly vie for dominance in a market projected to reach $100 billion. Uncover the challenges faced by payers amidst the soaring costs of lifelong treatment.

Explore the surprising science behind these drugs, originally developed for diabetes but now showing promise in curbing food cravings and addictive behaviors. Gain insights into their potential to redefine how doctors approach medicine and challenge societal perceptions of disease.

With debates on obesity definitions and medicalization heating up, this report navigates the complexities of a revolution just beginning. Embrace the era of Ozempic and beyond – the obesity revolution is here.